- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
New Survey—Clinical Trials: Past, Present and Future
SCORR Marketing announced a new survey report that was created in collaboration with Applied Clinical Trials-“Clinical Trials: Past, Present and Future”-is now available for free download.
The survey report describes what clinical trial professionals recognize as the biggest changes over the past decade, and what they expect as they continue evolving into the future.
While survey participants believe the increase in endpoints best explains the growing complexity of clinical trials over the past 10 years, they also predict an increase in the number of adaptive trials will lead to increasing clinical trial complexity in the future.
Clinical Trials: Past, Present and Future is available for download now at scorrmarketing.com.
Applied Clinical Trials published an article detailing perspectives from industry contributors looking at the complexity issues in drug development still to overcome. Read the article here
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
